 |
LONG BEACH, Calif., June 11, 2025 /PRNewswire/ -- At Augmented World Expo (AWE) 2025, RayNeo is poised to enthrall attendees with its latest innovation, the X3 Pro AR glasses. These full-color MicroLED waveguide AR glasses have achieved comprehensive breakthroughs across multiple key areas, including display quality, artificial intelligence capabilities, scenario-based applications, human–computer interaction, spatial sensing, and lightweight design. They are poised to set a new industry benchmark for consumer-grade full-color AR glasses.
The optical advancements of the X3 Pro are the result of a collaboration with Applied Materials, Inc. By integrating Applied Materials' etched waveguides with RayNeo's self-developed world's smallest Micro-LED light engine, the glasses deliver a cinematic-quality 43-inch, 16.7M-color 3D display.
Remarkably, this powerful visual experience is packed into an ultra-lightweight design weighing just 76 grams. The X3 Pro features an aerospace-grade magnesium alloy frame and titanium alloy hinge, combining high strength with durability while maintaining exceptional portability.
Powered by the first-generation Qualcomm® AR1 platform, the X3 Pro outperforms traditional prescription glasses in both functionality and comfort. Its innovative material selection and compact form factor make it one of the world's lightest full-color AR glasses, offering users a truly immersive yet burden-free experience.
In addition to significant hardware performance improvements, the application ecosystem of the RayNeo X3 Pro has also undergone a comprehensive evolution. The newly equipped RayNeoOS 2.0 system integrates a variety of practical functions, including AI translation, spatial navigation, AI recording, call transcription, and first-person photography and video recording. This offers users a smarter and more convenient experience.
On the interaction front, the RayNeo X3 Pro offers multiple intuitive control methods, including smartwatch input, five-way temple navigation, voice control, and smartphone linkage. These significantly boost operational efficiency. Features such as AR real-world navigation, speech-to-text transcription for calls, and spatial lyrics further propel full-color AR glasses from the lab into everyday life. For the first time, the X3 Pro has achieved Apple Watch control and supports a combination of various interaction methods, such as temple five-dimensional navigation, voice, and mobile phone linkage. This greatly improves interaction efficiency.
In terms of AI capabilities, the X3 Pro features a custom large-scale multimodal AI model for intuitive "Live AI" interactions. It can identify objects like buildings and books in real time using its dual-camera system, and offers instant translation. Acting as an "all-purpose intelligent guide," it simplifies cross-border travel and communication. RayNeo's new AI Agent App Store, with agents like DeepSeek and English tutoring, further integrates AI into daily life.
In terms of spatial perception, the RayNeo X3 Pro is equipped with the RayNeo Imaging Plus system, which can control spatial positioning errors within 5%. This enables the glasses to have a widely applicable spatial recognition capability. In terms of AI capabilities, the RayNeo X3 Pro has also taken a crucial step forward. The product is equipped with a first-person multimodal large model exclusively customized by Tongyi, becoming one of the first AR glasses in the world to support visual Live AI interaction. Whether walking, dining, or conversing, users can ask questions at any time and receive instant intelligent feedback.
Experience the Future of AR at AWE 2025
RayNeo invites industry professionals and enthusiasts to experience the groundbreaking capabilities of the X3 Pro AR glasses. Join us at Qualcomm Technologies, Booth 209, 203C, at the Long Beach Convention Center in California, from June 10th-12th. Witness firsthand how the X3 Pro is redefining the boundaries of augmented reality and transforming everyday interactions.
About RayNeo
RayNeo is a leading brand in the AR space, dedicated to redefining augmented reality through groundbreaking technology and wearable innovation. Initially incubated within TCL, RayNeo develops AR glasses that seamlessly integrate into everyday life, delivering immersive and intuitive experiences. By combining cutting-edge design with advanced technologies, RayNeo empowers users to explore and interact with the digital world like never before. Committed to shaping the future of AR, RayNeo drives innovation through collaboration and a user-first approach. For more information about RayNeo and its innovative AR technology, visit www.rayneo.com.
LONG BEACH, Calif., June 11, 2025 /PRNewswire/ -- At Augmented World Expo (AWE) 2025, RayNeo is poised to enthrall attendees with its latest innovation, the X3 Pro AR glasses. These full-color MicroLED waveguide AR glasses have achieved comprehensive breakthroughs across multiple key areas, including display quality, artificial intelligence capabilities, scenario-based applications, human–computer interaction, spatial sensing, and lightweight design. They are poised to set a new industry benchmark for consumer-grade full-color AR glasses.
The optical advancements of the X3 Pro are the result of a collaboration with Applied Materials, Inc. By integrating Applied Materials' etched waveguides with RayNeo's self-developed world's smallest Micro-LED light engine, the glasses deliver a cinematic-quality 43-inch, 16.7M-color 3D display.
Remarkably, this powerful visual experience is packed into an ultra-lightweight design weighing just 76 grams. The X3 Pro features an aerospace-grade magnesium alloy frame and titanium alloy hinge, combining high strength with durability while maintaining exceptional portability.
Powered by the first-generation Qualcomm® AR1 platform, the X3 Pro outperforms traditional prescription glasses in both functionality and comfort. Its innovative material selection and compact form factor make it one of the world's lightest full-color AR glasses, offering users a truly immersive yet burden-free experience.
In addition to significant hardware performance improvements, the application ecosystem of the RayNeo X3 Pro has also undergone a comprehensive evolution. The newly equipped RayNeoOS 2.0 system integrates a variety of practical functions, including AI translation, spatial navigation, AI recording, call transcription, and first-person photography and video recording. This offers users a smarter and more convenient experience.
On the interaction front, the RayNeo X3 Pro offers multiple intuitive control methods, including smartwatch input, five-way temple navigation, voice control, and smartphone linkage. These significantly boost operational efficiency. Features such as AR real-world navigation, speech-to-text transcription for calls, and spatial lyrics further propel full-color AR glasses from the lab into everyday life. For the first time, the X3 Pro has achieved Apple Watch control and supports a combination of various interaction methods, such as temple five-dimensional navigation, voice, and mobile phone linkage. This greatly improves interaction efficiency.
In terms of AI capabilities, the X3 Pro features a custom large-scale multimodal AI model for intuitive "Live AI" interactions. It can identify objects like buildings and books in real time using its dual-camera system, and offers instant translation. Acting as an "all-purpose intelligent guide," it simplifies cross-border travel and communication. RayNeo's new AI Agent App Store, with agents like DeepSeek and English tutoring, further integrates AI into daily life.
In terms of spatial perception, the RayNeo X3 Pro is equipped with the RayNeo Imaging Plus system, which can control spatial positioning errors within 5%. This enables the glasses to have a widely applicable spatial recognition capability. In terms of AI capabilities, the RayNeo X3 Pro has also taken a crucial step forward. The product is equipped with a first-person multimodal large model exclusively customized by Tongyi, becoming one of the first AR glasses in the world to support visual Live AI interaction. Whether walking, dining, or conversing, users can ask questions at any time and receive instant intelligent feedback.
Experience the Future of AR at AWE 2025
RayNeo invites industry professionals and enthusiasts to experience the groundbreaking capabilities of the X3 Pro AR glasses. Join us at Qualcomm Technologies, Booth 209, 203C, at the Long Beach Convention Center in California, from June 10th-12th. Witness firsthand how the X3 Pro is redefining the boundaries of augmented reality and transforming everyday interactions.
About RayNeo
RayNeo is a leading brand in the AR space, dedicated to redefining augmented reality through groundbreaking technology and wearable innovation. Initially incubated within TCL, RayNeo develops AR glasses that seamlessly integrate into everyday life, delivering immersive and intuitive experiences. By combining cutting-edge design with advanced technologies, RayNeo empowers users to explore and interact with the digital world like never before. Committed to shaping the future of AR, RayNeo drives innovation through collaboration and a user-first approach. For more information about RayNeo and its innovative AR technology, visit www.rayneo.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
RayNeo X3 Pro: Revolutionizing AR at AWE 2025
|
CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company's next-generation selective RET inhibitor, lunbotinib fumarate (A400/EP0031, 宁泰莱®[1]), in advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) were presented as an oral report by Professor Qing Zhou from Guangdong Provincial People's Hospital (Abstract #8505, Lung Cancer—Metastatic Non-Small Cell). Based on these results, a New Drug Application (NDA) for lunbotinib fumarate for the treatment of adult patients with locally advanced or metastatic RET fusion-positive NSCLC has been accepted by the National Medical Products Administration (NMPA) of China.
The study enrolled 71 patients who had previously received platinum-based chemotherapy and immunotherapy (pre-treated patients) and 92 patients who had not received prior systemic therapy (treatment-naïve patients). As of the data cutoff date of October 29, 2025, the median follow-up was 22.6 months and 20.7 months, respectively.
The confirmed objective response rate (ORR) assessed by Independent Review Committee (IRC) was 81.3% (95% CI: 71.8–88.7) in treatment-naïve patients and 87.1% (95% CI: 77.0–93.9) in pre-treated patients.
In treatment-naïve patients, median duration of response (mDOR) and median progression-free survival (mPFS) were not reached. In pre-treated patients, mDOR was 25.7 months, and mPFS was 27.5 months.
Among 40 patients with central nervous system (CNS) metastases at baseline (assessed by IRC per response assessment in neuro-oncology brain metastases (RANO-BM) criteria), the intracranial complete response (CR) rate was 30%, and the disease control rate (DCR) was 92.5% (95% CI: 79.6–98.4).
Lunbotinib fumarate was well tolerated, with treatment-related adverse events (TRAEs) being predominantly Grade 1–2. The rate of permanent discontinuation due to TRAEs was 1.2%, and no treatment-related deaths were reported.
The study shows that lunbotinib fumarate demonstrated robust and durable clinical activity in RET fusion-positive NSCLC, regardless of line of therapy, in a largely poor-prognostic patient population. Favorable CNS efficacy was observed in patients with measurable baseline CNS metastases. The safety profile was manageable, with no unexpected safety signals.
Professor Qing Zhou, principal investigator from Guangdong Provincial People's Hospital, said: "From the first presentation of Phase I data at ASCO 2023 to today's pivotal Phase II results, we have witnessed the progression of lunbotinib fumarate from early exploration to a confirmatory study. These data show that lunbotinib fumarate delivers robust and durable responses in both treatment-naïve and pre-treated patients with RET fusion-positive NSCLC, with particularly remarkable intracranial efficacy in patients with CNS metastases at baseline. As a next-generation selective RET inhibitor, it will offer an important new treatment option for patients."
| [1] Trade name to be approved by NMPA. |
|
About lunbotinib fumarate (A400/EP0031, 宁泰莱®)
Lunbotinib fumarate is a novel, next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of lunbotinib fumarate has been accepted for review by the NMPA of China for the treatment of adult patients with RET-fusion positive locally advanced or metastatic NSCLC. The Company is also conducting a Phase Ib/II clinical study in China for the treatment of RET-positive solid tumors.
In March 2021, the Company granted Ellipses Pharma Limited, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries. In April 2024, lunbotinib fumarate was cleared by the Food and Drug Administration (FDA) to progress into a Phase II clinical trial (NCT05443126) which is currently recruiting in the United States, United Kingdom, Europe and United Arab Emirates, where it is being evaluated as a monotherapy and in combination with chemotherapy in RET fusion positive advanced NSCLC.
About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.
CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company's next-generation selective RET inhibitor, lunbotinib fumarate (A400/EP0031, 宁泰莱®[1]), in advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) were presented as an oral report by Professor Qing Zhou from Guangdong Provincial People's Hospital (Abstract #8505, Lung Cancer—Metastatic Non-Small Cell). Based on these results, a New Drug Application (NDA) for lunbotinib fumarate for the treatment of adult patients with locally advanced or metastatic RET fusion-positive NSCLC has been accepted by the National Medical Products Administration (NMPA) of China.
The study enrolled 71 patients who had previously received platinum-based chemotherapy and immunotherapy (pre-treated patients) and 92 patients who had not received prior systemic therapy (treatment-naïve patients). As of the data cutoff date of October 29, 2025, the median follow-up was 22.6 months and 20.7 months, respectively.
The confirmed objective response rate (ORR) assessed by Independent Review Committee (IRC) was 81.3% (95% CI: 71.8–88.7) in treatment-naïve patients and 87.1% (95% CI: 77.0–93.9) in pre-treated patients.
In treatment-naïve patients, median duration of response (mDOR) and median progression-free survival (mPFS) were not reached. In pre-treated patients, mDOR was 25.7 months, and mPFS was 27.5 months.
Among 40 patients with central nervous system (CNS) metastases at baseline (assessed by IRC per response assessment in neuro-oncology brain metastases (RANO-BM) criteria), the intracranial complete response (CR) rate was 30%, and the disease control rate (DCR) was 92.5% (95% CI: 79.6–98.4).
Lunbotinib fumarate was well tolerated, with treatment-related adverse events (TRAEs) being predominantly Grade 1–2. The rate of permanent discontinuation due to TRAEs was 1.2%, and no treatment-related deaths were reported.
The study shows that lunbotinib fumarate demonstrated robust and durable clinical activity in RET fusion-positive NSCLC, regardless of line of therapy, in a largely poor-prognostic patient population. Favorable CNS efficacy was observed in patients with measurable baseline CNS metastases. The safety profile was manageable, with no unexpected safety signals.
Professor Qing Zhou, principal investigator from Guangdong Provincial People's Hospital, said: "From the first presentation of Phase I data at ASCO 2023 to today's pivotal Phase II results, we have witnessed the progression of lunbotinib fumarate from early exploration to a confirmatory study. These data show that lunbotinib fumarate delivers robust and durable responses in both treatment-naïve and pre-treated patients with RET fusion-positive NSCLC, with particularly remarkable intracranial efficacy in patients with CNS metastases at baseline. As a next-generation selective RET inhibitor, it will offer an important new treatment option for patients."
[1] Trade name to be approved by NMPA.
About lunbotinib fumarate (A400/EP0031, 宁泰莱®)
Lunbotinib fumarate is a novel, next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of lunbotinib fumarate has been accepted for review by the NMPA of China for the treatment of adult patients with RET-fusion positive locally advanced or metastatic NSCLC. The Company is also conducting a Phase Ib/II clinical study in China for the treatment of RET-positive solid tumors.
In March 2021, the Company granted Ellipses Pharma Limited, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries. In April 2024, lunbotinib fumarate was cleared by the Food and Drug Administration (FDA) to progress into a Phase II clinical trial (NCT05443126) which is currently recruiting in the United States, United Kingdom, Europe and United Arab Emirates, where it is being evaluated as a monotherapy and in combination with chemotherapy in RET fusion positive advanced NSCLC.
About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
